⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of AcuSurgical and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
AcuSurgical
↗Montpellier, France
AcuSurgical is a French medical device company founded in 2020 that specializes in developing advanced robotic systems for ophthalmic and vitreoretinal surgery. Its flagship technology, the Luca® system, is a bimanual, teleoperated robotic platform designed to provide micron-level precision, filter hand tremors, and stabilize instruments during delicate retinal procedures.
The company aims to redefine the standard of care for the over 300 million patients worldwide suffering from retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and macular holes. By enabling surgeons to operate with greater control and stability, AcuSurgical seeks to make complex retinal surgeries safer, more accessible, and capable of performing new procedures, such as subretinal gene therapy injections.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$7M
Investors:Mérieux Equity Partners, Supernova Invest, IRDI-Soridec, Sofimac Innovation
PIPELINE
Stage:Clinical
Lead Drug Stage:Clinical (First-in-human study completed)
Modalities:Robotic Surgery
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:LIRMM Robotics Laboratory (University of Montpellier/CNRS), Adolphe de Rothschild Foundation, Ghent University Hospital (Clinical trial partner)
COMPETITION
Position:Emerging
Competitors:Intuitive Surgical, Preceyes, Ophthorobotics
LEADERSHIP
Key Executives:
Ronen Castro - CEO
Christoph Spuhler - Co-founder
LINKS
Website:acusurgical.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with AcuSurgical. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.